LXEO | Lexeo Therapeutics, Inc. Common Stock Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	9.55 - 10.71
52 Week Range	7.86 - 22.33
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	198,018
Average Volume	300,418
Shares Outstanding	33,061,005
Market Cap	336,230,421
Sector	Healthcare
Industry	Biotechnology
IPO Date	2023-11-03

Valuation
Profitability
Growth
Health
P/E Ratio	-0.81
Forward P/E Ratio	N/A
EPS	-12.53
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	69
Country	USA
Website	LXEO

Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

*Chart delayed

Analyzing fundamentals for LXEO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see LXEO Fundamentals page.

Watching at LXEO technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on LXEO Technicals page.